Maintenance dosing information for ILARIS in the treatment of FMF, HIDS/MKD, TRAPS and CAPS.
ILARIS® (canakinumab) has a convenient 4-weekly maintenance dosing schedule1
In familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), ILARIS is administered as a subcutaneous injection once every 4 weeks.1
ILARIS has a convenient 8-weekly maintenance dosing schedule, and patients are able to receive treatment at home1
In cryopyrin-associated periodic syndromes (CAPS), ILARIS is administered as a subcutaneous injection once every 8 weeks.1
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:
- CAPS, including:
- Muckle-Wells syndrome (MWS)
- Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
- Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
- ILARIS should be given in combination with colchicine, if appropriate.
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; MKD, mevalonate kinase deficiency; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.
- ILARIS® (canakinumab) Summary of Product Characteristics.